Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11686761 | 0.98 | NOS1 (0.61) | NOS1FBP1 | |
| SCHEMBL28791532 | 0.83 | NOS1 (0.57) | NOS1FBP1 | |
| Hydrochloric Acid SCHEMBL6817134 | 0.79 | NOS1 (0.47) | NOS1FBP1 | |
| Praxadine SCHEMBL52095 | 0.77 | — | — | |
| Praxadine SCHEMBL3579034 | 0.77 | NOS1 (0.95) | NOS1FBP1 | |
| SCHEMBL8610230 | 0.77 | NOS1 (0.48) | NOS1FBP1 | |
| SCHEMBL19840582 | 0.76 | NOS1 (0.47) | NOS1FBP1 | |
| Hydrochloric Acid SCHEMBL18585884 | 0.76 | NOS1 (0.47) | NOS1FBP1 | |
| Praxadine SCHEMBL94070 | 0.74 | — | — | |
| SCHEMBL14275238 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117358321-B | Chromatography medium and preparation method thereof | 赛普(杭州)过滤科技有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-117358321-A | Chromatography medium and preparation method thereof | 赛普(杭州)过滤科技有限公司 | 2024-01-09 | — | — | CN | claimed |
| CN-116899633-B | Hydrophilic anion exchange chromatography medium and preparation method and application thereof | 赛普(杭州)过滤科技有限公司 | 2023-12-19 | — | — | CN | claimed |
| CN-116899633-A | Hydrophilic anion exchange chromatography medium and preparation method and application thereof | 赛普(杭州)过滤科技有限公司 | 2023-10-20 | — | — | CN | claimed |
| US-20250235390-A1 | Composition and Process for Treating a Disorder in the Oral Cavity of a Mammal | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2025-07-24 | — | — | US | disclosed |
| EP-3534867-B1 | MEDICAL COMPOSITION CONTAINING GUANIDINYL-CONTAINING POLYMER(S) AND CARRAGEENANE(S) | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-3534866-B1 | METHOD OF DENTAL RETRACTION WITH COMPOSITION WITH GUANIDINYL-CONTAINING POLYMER | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-05-28 | — | — | EP | disclosed |
| US-12295369-B2 | Articles containing a crosslinked guanidinyl-containing polymer and uses thereof | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-05-13 | — | — | US | disclosed |
| CN-119896762-A | Process monitoring device | 舒万诺知识产权公司 | 2025-04-29 | — | — | CN | disclosed |
| US-20250082440-A1 | Composition for Isolating Tissue | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2025-03-13 | — | — | US | disclosed |
| EP-4419062-A1 | COMPOSITION AND PROCESS FOR TREATING A DISORDER IN THE ORAL CAVITY OF A MAMMAL | Solventum Intellectual Properties Company (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-114173560-B | Articles comprising crosslinked guanidine-containing polymers and uses thereof | 舒万诺知识产权公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2014209798-A1 | WIPE WITH A GUANIDINYL-CONTAINING POLYMER | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014204763-A1 | PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014088807-A1 | GUANIDINE-FUNCTIONALIZED PARTICLES AND METHODS OF MAKING AND USING | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20130224825-A1 | LIGAND FUNCTIONALIZED POLYMERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130217032-A1 | LIGAND FUNCTIONALIZED POLYMERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-08-22 | — | — | US | disclosed |
| US-8435776-B2 | Ligand functionalized polymers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-05-07 | — | — | US | disclosed |
| US-20110217752-A1 | LIGAND FUNCTIONALIZED POLYMERS | 3M INNOVATIVE PROPERTIES COMPANY | 2011-09-08 | — | — | US | disclosed |
| US-4017539-A | Biguanide compounds and anti-diabetic compositions | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1977-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12295369-B2 | Articles containing a crosslinked guanidinyl-containing polymer and uses thereof | C5, YTHDC1, PRMT1 | NOS1 440/4885FBP1 4567/4885 |
| US-20250235390-A1 | Composition and Process for Treating a Disorder in the Oral Cavity of a Mammal | GSDMD, PIGS, GANC | NOS1 2835/4885FBP1 4401/4885 |
| US-20130224825-A1 | LIGAND FUNCTIONALIZED POLYMERS | SELPLG, CD69, SIGLEC7 | NOS1 3048/4885FBP1 775/4885 |
| US-20110217752-A1 | LIGAND FUNCTIONALIZED POLYMERS | SELPLG, CD69, SIGLEC7 | NOS1 3048/4885FBP1 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.